These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16822063)

  • 1. In-vivo imaging of tumor associated urokinase-type plasminogen activator activity.
    Hsiao JK; Law B; Weissleder R; Tung CH
    J Biomed Opt; 2006; 11(3):34013. PubMed ID: 16822063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.
    Madsen MA; Deryugina EI; Niessen S; Cravatt BF; Quigley JP
    J Biol Chem; 2006 Jun; 281(23):15997-6005. PubMed ID: 16611636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
    Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
    Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of plasminogen activator activity from human fibrosarcoma cells by a new microassay.
    Rezaee M; Chen L; Kramer RH
    Int J Cancer; 1987 Dec; 40(6):823-9. PubMed ID: 3692627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin.
    Wilcox SA; Reho T; Higgins PJ; Tominna-Sebald E; McKeown-Longo PJ
    Biochem Cell Biol; 1996; 74(6):899-910. PubMed ID: 9164658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
    Illemann M; Bird N; Majeed A; Laerum OD; Lund LR; Danø K; Nielsen BS
    Int J Cancer; 2009 Apr; 124(8):1860-70. PubMed ID: 19123477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
    Tsuchiya H; Katsuo S; Matsuda E; Sunayama C; Tomita K; Ueda Y; Binder BR
    Gen Diagn Pathol; 1995 May; 141(1):41-8. PubMed ID: 8542506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
    Reilly D; Andreasen PA; Duffy MJ
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):47-50. PubMed ID: 1772998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
    Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
    Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter.
    Law B; Curino A; Bugge TH; Weissleder R; Tung CH
    Chem Biol; 2004 Jan; 11(1):99-106. PubMed ID: 15112999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of [
    Vangestel C; Thomae D; Van Soom J; Ides J; Wyffels L; Pauwels P; Stroobants S; Van der Veken P; Magdolen V; Joossens J; Augustyns K; Staelens S
    Contrast Media Mol Imaging; 2016 Nov; 11(6):448-458. PubMed ID: 27558262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
    Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
    Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
    J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
    Sweep CG; Geurts-Moespot J; Grebenschikov N; de Witte JH; Heuvel JJ; Schmitt M; Duffy MJ; Jänicke F; Kramer MD; Foekens JA; Brünner N; Brugal G; Pedersen AN; Benraad TJ
    Br J Cancer; 1998 Dec; 78(11):1434-41. PubMed ID: 9836475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
    Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
    Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
    Grøndahl-Hansen J; Ralfkiaer E; Kirkeby LT; Kristensen P; Lund LR; Danø K
    Am J Pathol; 1991 Jan; 138(1):111-7. PubMed ID: 1702928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serine proteinase activation in esophageal cancer.
    Tang WH; Friess H; Kekis PB; Martignoni ME; Fukuda A; Roggo A; Zimmerman A; Büchler MW
    Anticancer Res; 2001; 21(4A):2249-58. PubMed ID: 11724279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines.
    Okusa Y; Ichikura T; Mochizuki H; Shinomiya N
    Int J Oncol; 2000 Nov; 17(5):1001-5. PubMed ID: 11029504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
    Duffy MJ; O'Grady P; Devaney D; O'Siorain L; Fennelly JJ; Lijnen HJ
    Cancer; 1988 Aug; 62(3):531-3. PubMed ID: 3134120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.